of adenosine are rapid in onset (5-30 seconds) and transient; adenosine's half-life is 10-30 seconds because it is quickly taken up and metabolized by adenosine deaminase in erythrocytes and by endothelial cells."
These differing regional cardiac effects and short half-life have led to the use of adenosine in the treatment of cardiac arrhythmias. Adenosine can terminate supraventricular arrhythmias in 86-100% of cases if the AV node is involved in the genesis of the arrhythmia; for example, in AV and AV-nodal reentry arrhythmias.12-'5 However, the arrhythmia may recur quickly in up to one third of cases after the effects of adenosine dissipate. '4 Adenosine will rarely terminate tachyarrhythmia of atrial origin. Rather, adenosine may be of diagnostic value because it slows the ventricular rate by causing block at the AV node and reveals the unaffected atrial arrhythmia, as in automatic atrial tachycardia, atrial flutter, and atrial fibrillation.'2-15 Although adenosine is not effective in terminating ventricular tachycardia, it has been safely and effectively used to help differentiate ventricular tachycardia from supraventricular tachycardia with a wide QRS complex.13-'5 It appears to be a safer choice for this procedure than verapamil,"1"4 which often has deleterious hemodynamic effects in patients with ventricular tachycardia.
In an interesting case report aminophylline, an adenosine antagonist, reversed atropine-resistant AV block following acute inferior myocardial infarction. 16 This suggests that persistent ischemia or hypoxia may cause high tissue levels of adenosine leading to bradycardia or AV block. It also suggests a possible therapeutic role for adenosine antagonists in atropine-resistant AV block. The possible role of adenosine in sick sinus syndrome or profound bradycardia has not been adequately investigated.
Side effects have been reported to occur in 24-64% of the patients given adenosine.12-15 These include dyspnea (perhaps due to bronchospasm), chest pain, flushing, hypotension, nausea, vomiting, and headache. Although transient (usually lasting less than 1 minute), patients often judged the symptoms as moderate to severe. Major adverse hemodynamic changes have rarely been noted. However, high degrees of AV block with prolonged pauses (2-6 seconds) have occurred.'2'14 Aminophylline, caffeine, and other methylxanthines antagonize the actions of adenosine,1217 whereas dipyridamole18,19 and denervation of the heart20 potentiate the sinoatrial (SA) and AV node effect of adenosine threefold to sevenfold. Thus, the use of adenosine in patients with underlying conduction disease, or in those receiving other drugs that impair AV conduction or that may interact with adenosine, is not recommended or, if judged important, should be done with a reduced dosage and with extreme care. Adenosine also has some proarrhythmic effects. The development of atrial fibrillation and ventricular extrasystoles has been infrequently noted. 12 Important information about the adequacy of coronary flow can be obtained during pharmacologically induced maximum or near-maximum increases in flow. This enables measurement of coronary flow reserve and the detection of inadequate flow to a region of the myocardium by thallium-201 scintigraphy and by echocardiographic imaging to detect wall motion abnormalities. Papaverine and dipyridamole, the two most commonly used coronary vasodilator agents in humans, are not ideal for this purpose because of their long half-lives and duration of action and the prolongation of the QT interval and induction of arrhythmias that they cause.27 Adenosine could be a more suitable agent for repeatedly inducing maximum coronary vasodilation because of its rapid onset and offset of action. Its use in humans has been limited mainly because of side effects reported by patients and the AV node block produced. In addition, only a mild vasodilator effect had been previously noted with bolus injections. 7, 28 Renewed interest in adenosine as a coronary vasodilator occurred with reports that maximum and sustained vasodilation could be achieved without the adverse effects on the conduction system when it was given as a continuous low-dose infusion. In this issue of Circulation, Wilson and colleagues27 provide detailed and helpful information about the use, efficacy, and safety of intravenous and intracoronary adenosine in humans.
The strengths of this study27 are 1) the administration of adenosine by three modes (intracoronary bolus, continuous intracoronary infusion, and continuous intravenous infusion), 2) a careful description of the dose-response kinetics for each mode of adenosine administration, and 3) comparison of the vasodilatory responses to intracoronary and intravenous adenosine with those to intracoronary papaverine (the gold standard). They found that intracoronary adenosine induces coronary vasodilation equivalent to that generated by papaverine without causing important changes in systemic hemodynamics or the electrocardiogram. Intravenous adenosine at as much as 140 ,ug/kg/min for at least 2 minutes caused coronary vasodilation similar to that caused by papaverine in 83% of patients. A mild dosedependent fall in mean arterial pressure and a rise in heart rate occurred during the intravenous administration. Adverse symptoms or effects on the conduction system were uncommon. A finding not well described was that intravenous adenosine infusion at dosages just below that required to achieve maximum vasodilation (70-100 ,g/kg/min) frequently caused a pattern of fluctuating flow. This pattern disappeared when the infusion rate was increased.
These results clearly establish that intracoronary and intravenous infusions of adenosine effectively induce coronary vasodilation to the same degree as does intracoronary papaverine. The safety and effectiveness of the intravenous infusion of adenosine is important because this route of administration would greatly simplify its clinical use as a coronary vasodilator.
The authors are appropriately cautious in interpreting and generalizing their results. Although the data are encouraging, it must be remembered that they studied only 36 individuals who had normal coronary arteries and normal left ventricular function. The highest intravenous dosage (140 ,g/kg/ min) was given for approximately 2 minutes. The safety of longer infusions, which would likely be necessary in clinical studies, was not determined. The effectiveness and safety of adenosine in people with significant coronary obstructions, left ventricular dysfunction, ventricular hypertrophy, predisposition to arrhythmias, or SA or AV node disease needs to be established. Interactions between adenosine and other drugs need to be better defined. Additional information might be desirable regarding the frequency, significance, and mechanism of the fluctuations noted in coronary flow at the lower infusion rates of adenosine.
Conclusions
After a long history of use in experimental animal studies, adenosine now appears to have real and potential uses in humans. The safety and efficacy of adenosine in the diagnosis and treatment of supraventricular tachyarrhythmias are now established. The role adenosine plays in myocardial ischemia is being explored, including its part in causing anginalike chest pain and also in counteracting ischemia or reperfusion-induced myocardial injury. Finally, adenosine holds promise as a safe and effective coronary vasodilator that could be useful in studying the normal and abnormal coronary circulation in humans. [29] [30] [31] 
